New hope for deadly thyroid cancer: testing a powerful drug duo
NCT ID NCT06374602
Summary
This study is testing whether a combination of two existing drugs, pembrolizumab and lenvatinib, can help control a very aggressive and hard-to-treat form of thyroid cancer. It will involve about 20 adults with anaplastic thyroid cancer that cannot be fully removed by surgery. The main goals are to see if the treatment shrinks tumors, how long the benefit lasts, and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint Petersburg State University Hospital
RECRUITINGSaint Petersburg, 190020, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.